According to IMARC Group latest published report, titled “Dry Eye Syndrome Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” that The global dry eye syndrome market size reached US$ 4.5 Billion in 2022. Looking forward, the market expected to reach US$ 6.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.67% during 2023-2028.
The report also includes competitor and regional analysis, and contemporary advancements in the global market.
Dry eye syndrome is a common condition that causes the inability of the human eyes to produce or maintain a sufficient quantity and quality of natural tears to lubricate the eyes. It causes disturbance of the lacrimal functional unit consisting of the lacrimal glands, ocular surface, lids, and the sensory and motor nerves that connect them. As a result, it damages the surface of the eyes leading to pain, irritation, and inflammation, affecting the vision of individuals. It is caused by various factors, including excessive exposure to digital screens, allergies, aging, menopause, smoking, LASIK eye surgery, as well as hormone replacement therapy.
Download free sample of the report: https://www.imarcgroup.com/dry-eye-syndrome-market/requestsample
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Competitive Landscape
The report has also examined the competitive landscape of global dry eye syndrome market. Some of the major players in the market are Novartis AG, Allergan plc., Otsuka Holdings Co., Ltd., Santen Pharmaceutical Co., Ltd., Nicox S.A., Auven Therapeutics, Akorn, Inc., Bausch + Lomb, Alimera Science and GlaxoSmithKline plc.
Market Trends
The market is primarily driven by the rising geriatric population, which is prone to low levels of supportive hormones, inflammatory diseases, and ocular surface diseases. In addition, the growing number of surgeries that affect the cholinergic nerves, which stimulate tear secretion, are also contributing to the rise in dry eye-related diseases. Factors such as increasing treatment options available to patients and inflating income levels of individuals are significantly impacting the market growth. Moreover, the increasing awareness regarding the diagnosis and treatment of the disease is also providing a positive market outlook. As a result, manufacturers are increasingly launching new treatments, such as short-term treatments for dry eye, which enhance the penetration of loteprednol etabonate into the target ocular surface tissue and treat its signs and symptoms.
Ask An Analyst – https://www.imarcgroup.com/request?type=report&id=1136&flag=C
Dry Eye Syndrome Market Segmentation:
The report has segmented on the basis of Disease Type, Product, distribution channel and geography.
Segmentation by Disease Type
• Evaporative Dry Eye Syndrome
• Aqueous Dry Eye Syndrome
• Breakup by Drug Type
• Lubricant Eye Drops
• Anti-inflammatory Drugs
• Autologous Serum Eye Drops
Segmentation by Product
• Liquid Drops
• Gel
• Liquid Wipes
• Eye Ointment
• Others
Segmentation by Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
Segmentation by Region
• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America
Key highlights of the report:
• Market Performance
• Market Outlook
• Porter’s Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Competitive Structure
• Profiles of Key Players
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact us
IMARC Group
Website: https://www.imarcgroup.com
Email: sales@imarcgroup.com
USA: +1-631-791-1145
Follow us on twitter: @imarcglobal